Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide
Obesity drug retatrutide targets glucose-dependent insulinotropic polypeptide receptors, glucagon-like peptide-1 receptors and glucagon receptors
Unregulated or improperly used GLP-1 drugs can cause anxiety, mood changes, and in some cases, worsen depression or eating disorder symptoms especially in individuals with pre-existing mental health conditions
Rapid reductions in body weight may sometimes include: Lean mass loss Declining resting energy expenditure Metabolic adaptation Reduced metabolic flexibility This is one reason future therapies may increasingly focus on: Body composition preservation Lean mass maintenance Metabolic resilience Sustainable long-term outcomes The conversation is gradually shifting from: How much weight was lost? toward: What happened to metabolism, muscle, and long-term sustainability? Why Researchers Are Paying Attention The interest surrounding retatrutide is not simply about larger weight loss numbers
Low-Income Subsidy cost-sharing reductions do not apply to the Bridge copay
Theyre not designed to cure the condition
.webp)
